SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: hillary kapan who wrote (668)2/14/1998 9:42:00 PM
From: David Cathcart  Read Replies (1) of 1826
 
Thanks Hillary...

More of Blitzer's comments from the conference call on Wednesday:

"In early January we held another advisory panel meeting for MGI 114 and were encouraged by the enthusiasm for the drug's development. The oncologists who attended are all as anxious as we are to move into phase II due to the numerous possibilities this drug has in treating a number of tumor types. The National Cancer Institute also sent a representative to participate in this meeting to insure that they as up to speed on the development of this drug as everyone else."

"...I would like comment on our quest for an international partner for MGI 114. During the last quarter we continued to hold in-depth conversations with a number of companies relative to their interest in becoming our marketing partner for markets outside the United States. Because of the continuing interest on the part of these companies, and the ongoing development of the drug itself, we remain ever confident that we will enter into a solid international partnership for MGI 114. And of course I look forward to the day that we can make a conclusive announcement about such a relationship."

Now let's go shrink some tumors!

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News